BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21444869)

  • 1. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
    Mikkelsen TS; Sparreboom A; Cheng C; Zhou Y; Boyett JM; Raimondi SC; Panetta JC; Bowman WP; Sandlund JT; Pui CH; Relling MV; Evans WE
    J Clin Oncol; 2011 May; 29(13):1771-8. PubMed ID: 21444869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
    Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
    J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.
    Lopez-Lopez E; Autry RJ; Smith C; Yang W; Paugh SW; Panetta JC; Crews KR; Bonten EJ; Smart B; Pei D; McCorkle JR; Diouf B; Roberts KG; Shi L; Pounds S; Cheng C; Mullighan CG; Pui CH; Relling MV; Evans WE
    J Clin Invest; 2020 Dec; 130(12):6600-6615. PubMed ID: 33164984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.
    Panetta JC; Yanishevski Y; Pui CH; Sandlund JT; Rubnitz J; Rivera GK; Ribeiro R; Evans WE; Relling MV
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):419-28. PubMed ID: 12439601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
    Panetta JC; Sparreboom A; Pui CH; Relling MV; Evans WE
    PLoS Comput Biol; 2010 Dec; 6(12):e1001019. PubMed ID: 21152005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
    Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
    Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
    Kager L; Cheok M; Yang W; Zaza G; Cheng Q; Panetta JC; Pui CH; Downing JR; Relling MV; Evans WE
    J Clin Invest; 2005 Jan; 115(1):110-7. PubMed ID: 15630450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.
    Synold TW; Relling MV; Boyett JM; Rivera GK; Sandlund JT; Mahmoud H; Crist WM; Pui CH; Evans WE
    J Clin Invest; 1994 Nov; 94(5):1996-2001. PubMed ID: 7525652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
    Nersting J; Nielsen SN; Grell K; Paerregaard M; Abrahamsson J; Lund B; Jonsson OG; Pruunsild K; Vaitkeviciene G; Kanerva J; Schmiegelow K;
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):53-60. PubMed ID: 30324220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
    Dervieux T; Hancock M; Evans W; Pui CH; Relling MV
    Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Whitehead VM; Vuchich MJ; Lauer SJ; Mahoney D; Carroll AJ; Shuster JJ; Esseltine DW; Payment C; Look AT; Akabutu J
    Blood; 1992 Sep; 80(5):1316-23. PubMed ID: 1381244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights.
    Rajšić I; Lazarević S; Đanić M; Al-Salami H; Mooranian A; Vukmirović S; Mikov M; Goločorbin-Kon S
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):127-134. PubMed ID: 34637107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Whitehead VM; Shuster JJ; Vuchich MJ; Mahoney DH; Lauer SJ; Payment C; Koch PA; Cooley LD; Look AT; Pullen DJ; Camitta B
    Leukemia; 2005 Apr; 19(4):533-6. PubMed ID: 15716987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
    Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
    Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
    Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
    Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children.
    de Beaumais TA; Jacqz-Aigrain E
    Curr Drug Metab; 2012 Jul; 13(6):822-34. PubMed ID: 22571483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.
    Belkov VM; Krynetski EY; Schuetz JD; Yanishevski Y; Masson E; Mathew S; Raimondi S; Pui CH; Relling MV; Evans WE
    Blood; 1999 Mar; 93(5):1643-50. PubMed ID: 10029593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity.
    Panetta JC; Wall A; Pui CH; Relling MV; Evans WE
    Clin Cancer Res; 2002 Jul; 8(7):2423-9. PubMed ID: 12114448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.